AAB Calls For Inclusion of Biotech Provisions in the FY26 National Defense Authorization Act (NDAA)

The AAB joined with 32 other leaders in the U.S. biomanufacturing sector calling for the inclusion of the biotechnology provisions in the Fiscal Year 2026 National Defense Authorization Act (NDAA). The letter notes that the National Security Commission on Emerging Biotechnology (NSCEB) concluded that:

"Advances in biotechnology represent a paradigm shift in how conflicts can be fought and won. The countries that seize the moment will retain or achieve superpower status. Those that fail to do so will not only fall behind but also become vulnerable to the use of biotechnology against them."

Congress is starting the process of reconciling the House and Senate-passed versions of the FY2026 NDAA. The letter calls for all provisions to be included in the final bill.

NDAA Final Letter 10.27.25.pdf

Download PDF • 278KB